FDA has accepted for review a supplemental Biologics License Application seeking approval for Keytruda as a single agent for the treatment of patients with advanced endometrial carcinoma that is microsatellite instability-high or mismatch repair deficient, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
The windows down the hall from the operating room scrub sinks at MD Anderson Cancer Center look out at the tower of Texas Children’s Hospital.
